RSS SubscribeAddiction
June 17, 2021
Entheon Biomedical appears to be well on its way to developing a safe and effective solution for treating addiction and substance-use disorders, potentially changing the way society approaches drug addiction.
In April the company launched the industry’s first psychedelics genetic test kit, setting it on a path to creating more value out of data and technology to serve its customers.
In April the company launched the industry’s first psychedelics genetic test kit, setting it on a path to creating more value out of data and technology to serve its customers.
April 10, 2021
As pioneers of a leading-edge addiction recovery solution based on psychedelic medicine, Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) has been actively expanding its business over the past weeks. The culmination of that work is the release of a potentially groundbreaking product in the field of psychedelic therapy, which would also represent the company’s first revenue stream.
February 18, 2021
2021.02.18 Despite improvements in medical technology and billions of dollars injected into treatment […]
January 16, 2021
2021.01.16 Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) has completed its first deal […]
December 2, 2020
Entheon Biomedical hires Dutch research firm to conduct human clinical trial of psychedelic drug DMT
2020.12.02 Opioids belong to a class of medications used to treat pain. Examples […]
November 28, 2020
2020.11.28 Opioids belong to a class of medications used to treat pain. Examples […]
November 12, 2020
2020.11.12 Psychedelic drugs, or sometimes called hallucinogens, are shrouded in a mist of […]
November 30, 2019
2019.11.30 Fifty-three years after LSD was banned by the FDA, psychedelic drugs are […]